Search Results

1 - 10 of 1,839 items :

  • "biomarkers" x
Clear All
Biomarkers in COPD – Challenging, Real or Illusive

REFERENCES 1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. 2. Clark KD, Wardrobe-Wong N, Elliott JJ, et al. Patterns of lung disease in a “normal” smoking population: are emphysema and airflow obstruction found together? Chest 2001;120(3):743-7. 3. Cote CG. Surrogates of mortality in chronic obstructive pulmonary disease. Am J Med 2006;119(10 Suppl 1):S54-S62. 4. Abu Hussein N, Ter Riet G, Schoenenberger L, et al. The ADO index

Open access
Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

. Eur Respir J . 2012;39:1354-1360. 9. Liesker JJ, Bathoorn E, Postma DS et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med . 2011;105:1853-1860. 10. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med . 2014;35:131-141. 11. Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respir Res . 2013;14:111. 12. Barnes P, Chowdhury B, Kharitonov S, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J

Open access
Urine biomarkers in renal allograft

frequent invasive or non-invasive procedures. A biomarker is defined as a “cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention.[ 8 ] The serum creatinine is a poor marker of early renal dysfunction, because the serum concentration is greatly influenced by numerous non-renal factors (such as body weight, race, age, gender, total body volume, drugs, muscle metabolism, and protein intake).[ 9

Open access
MicroRNAs as Biomarkers and Therapeutic Targets in Heart Failure

References 1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. - 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200 2. Morrow DA, de Lemos JA. Benchmarks for the assessment of cardiovascular biomarkers. Circulation. 2007

Open access
Changes in synovial fluid biomarkers after experimental equine osteoarthritis

marker in serum and synovial fluid in an equine model of arthritis. Vet Immunol Immunopathol 2016, 182, 74–78. 4. Clegg P.D., Coughlan A.R., Riggs C.M., Carter S.D.: Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997, 29, 343–348. 5. de Bakker E., Stroobants V., VanDael F., Ryssen B.V., Meyer E.: Canine synovial fluid biomarkers for early detection and monitoring of osteoarthritis. Vet Rec 2017, 180, 328–329. 6. de Grauw J.C., van de Lest C.H.A., van Weeren P.R.: Inflammatory mediators and cartilage biomarkers in synovial

Open access
Recent Advances in Biomarker Discovery — from Serum to Imaging-based Biomarkers for a Complex Assessment of Heart Failure Patients

REFERENCES 1. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol . 2010;55:2062-2076. 2. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol . 2011;58:1881-1889. 3. Ndumele CE, Matsushita K, Sang Y, et al. N-Terminal Pro-Brain Natriuretic Peptide

Open access
Blood-based biomarkers in Alzheimer’s disease: an overview on proteomic and lipidomic approaches

assessment of change in fibrillary amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending- dose study. Lancet Neurol. 2010 Apr; 9(4):363-72. DOI: 10.1016/S1474-4422(10)70043-0. 7. Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease - are we on the right road? N Engl J Med. 2014 Jan 23; 370(4):377-8. DOI: 10.1056/NEJMe1313943. 8. Bier JC. Biomarkers of Alzheimer’s disease: concepts and clinical case. Rev Med Brux. 2013 Sep. 34

Open access
What is a Biomarker? From its Discovery to Clinical Application

References Biomarkers Definition Working Group. Biomarkers and su rrogate end-point: preferred definitions and conceptual frame work. Clin Pharmacol Ther 2001; 69: 89-95. Manolio T. Novel Risk markers and clinical practice. N Engl J Med 2003; 349: 1587-9. Dickstein K, Cohen-Solal A, Filippatos G, et al. for the Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute

Open access
Biomarkers in Community-Acquired Pneumonia Assessment

-Donne, I., Rossi, R., Colombo, R., Giustarini, D., Milzani, A. (2006). Biomarkers of oxidative damage in human disease. Clin. Chem., 52 (4), 601-623. Day, B. J. (2005). Glutathione: A radical treatment for cystic fibrosis lung disease. Chest, 127 (1), 12-14. Esterbauer, H., Cheesman K. (1990). Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol., 186, 407-421. File, T. (2003). Community-acquired pneumonia. Lancet, 362, 1991-2001. Fine, M., Auble, T

Open access
Biomarkers in the diagnosis and prognostic assessment of acute respiratory distress syndrome

, Korevaar JC, Schultz MJ. Clara Cell Protein and Surfactant Protein D Plasma Levels are Associated with Clinical Outcomes of Mechanically Ventilated Patients. J Pulmon Resp Med 2013;3:138. 4. Determann RM, Royakkers AA, Haitsma JJ, Zhang H, Slutsky AS, Ranieri VM. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 2010;10:6. 5. Kuzovlev A, Moroz V, Goloubev A, Polovnikov S. Biomarkers for early stage of acute respiratory distress syndrome in septic

Open access